{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:13:37Z","timestamp":1790842417219,"version":"4.1.0"},"reference-count":58,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37-CA262362"],"award-info":[{"award-number":["R37-CA262362"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["Clinical Scientist Development Grant"],"award-info":[{"award-number":["Clinical Scientist Development Grant"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Robert A. Winn Diversity in Clinical Trials Career Development Award","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Berman and Maguire Funds for Lymphoma Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["Scholar in Clinical Research Award"],"award-info":[{"award-number":["Scholar in Clinical Research Award"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012200","name":"Laffey McHugh Foundation","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100012200","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-cell malignancies, and additional indications are being evaluated. In this review, we survey data on how outcomes after CAR-T therapies vary according to age, race, and ethnicity. We also review the representation of age, racial, and ethnic groups in key CAR-T clinical trials. We focus on B-cell acute lymphoblastic leukemia, B-cell non-Hodgkin\u2019s lymphoma, and multiple myeloma.<\/jats:p>","DOI":"10.1136\/jitc-2024-009349","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:16Z","timestamp":1737676816000},"page":"e009349","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-3579","authenticated-orcid":false,"given":"Guido","family":"Ghilardi","sequence":"first","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainul S.","family":"Hasanali","sequence":"additional","affiliation":[{"name":"Department of Medicine and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"Susanibar-Adaniya","sequence":"additional","affiliation":[{"name":"Department of Medicine and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena E.","family":"Winestone","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and BMT, Department of Pediatrics, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"},{"name":"Department of Medicine and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[{"name":"Department of Medicine and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"2025100308224116000_13.1.e009349.1","unstructured":"NIMHD . Minority health and health disparities: definitions, parameters. 2024. Available: https:\/\/www.nimhd.nih.gov\/about\/strategic-plan\/nih-strategic-plan-definitions-and-parameters.html"},{"key":"2025100308224116000_13.1.e009349.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100308224116000_13.1.e009349.3","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"2025100308224116000_13.1.e009349.4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00371-4"},{"key":"2025100308224116000_13.1.e009349.5","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021012727","article-title":"Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy","volume":"139","author":"Leahy","year":"2022","journal-title":"Blood"},{"key":"2025100308224116000_13.1.e009349.6","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1038\/s41375-021-01133-4","article-title":"Increased Incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic\/Latino children-a novel health disparity","volume":"35","author":"Raca","year":"2021","journal-title":"Leukemia"},{"key":"2025100308224116000_13.1.e009349.7","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","article-title":"The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes","volume":"6","author":"Faruqi","year":"2022","journal-title":"Blood Adv"},{"key":"2025100308224116000_13.1.e009349.8","article-title":"Outcomes of Hispanic and non-Hispanic white pediatric and young adult patients with B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel","volume":"40","author":"Vandris","year":"2022","journal-title":"J C O"},{"key":"2025100308224116000_13.1.e009349.9","article-title":"Racial disparities and inequity in clinical trials of chimeric antigen receptor T-cell therapy","volume":"41","author":"Thakur","year":"2023","journal-title":"J C O"},{"key":"2025100308224116000_13.1.e009349.10","unstructured":"Baggott C , Kunicki M , Prabhu S , et al . Inferior outcomes among black patients with childhood acute lymphoblastic leukemia following tisagenlecleucel. tandem meetings. 2021. Available: https:\/\/tct.confex.com\/tandem\/2021\/meetingapp.cgi\/Paper\/18094"},{"key":"2025100308224116000_13.1.e009349.11","first-page":"356","article-title":"Access to Chimeric Antigen Receptor T Cell Clinical Trials in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult Acute Lymphobastic Leukemia Patients","volume":"29","author":"Hall","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025100308224116000_13.1.e009349.12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.2022017866","article-title":"Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy","volume":"141","author":"Newman","year":"2023","journal-title":"Blood"},{"key":"2025100308224116000_13.1.e009349.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"2025100308224116000_13.1.e009349.14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726893"},{"key":"2025100308224116000_13.1.e009349.15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jtct.2023.10.005","article-title":"INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia","volume":"30","author":"Winestone","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025100308224116000_13.1.e009349.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"2025100308224116000_13.1.e009349.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"2025100308224116000_13.1.e009349.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"2025100308224116000_13.1.e009349.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2"},{"key":"2025100308224116000_13.1.e009349.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100308224116000_13.1.e009349.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"2025100308224116000_13.1.e009349.22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-Year Follow-Up of KTE-X19 in Patients With Relapsed\/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100308224116000_13.1.e009349.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"2025100308224116000_13.1.e009349.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0"},{"key":"2025100308224116000_13.1.e009349.25","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100308224116000_13.1.e009349.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2024.01.006","article-title":"Geographic and Racial Disparities in Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma","volume":"24","author":"Shahzad","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025100308224116000_13.1.e009349.27","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300213","article-title":"CAR T-Cell Immunotherapy in Minority Patients with Lymphoma","volume":"3","author":"Ghilardi","year":"2024","journal-title":"NEJM Evid"},{"key":"2025100308224116000_13.1.e009349.28","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"2025100308224116000_13.1.e009349.29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"key":"2025100308224116000_13.1.e009349.30","first-page":"581","article-title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2025100308224116000_13.1.e009349.31","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-120013","article-title":"Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma","volume":"132","author":"Sano","year":"2018","journal-title":"Blood"},{"key":"2025100308224116000_13.1.e009349.32","article-title":"Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study","volume":"8","author":"Berning","year":"2024","journal-title":"Hem"},{"key":"2025100308224116000_13.1.e009349.33","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"2025100308224116000_13.1.e009349.34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","article-title":"Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience","volume":"58","author":"Dreger","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2025100308224116000_13.1.e009349.35","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"},{"key":"2025100308224116000_13.1.e009349.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"2025100308224116000_13.1.e009349.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"2025100308224116000_13.1.e009349.38","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022268103136"},{"key":"2025100308224116000_13.1.e009349.39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-298760"},{"key":"2025100308224116000_13.1.e009349.40","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"},{"key":"2025100308224116000_13.1.e009349.41","unstructured":"Cancer stat facts: myeloma. National Cancer Institute Surveillance, Epidemiology, and End Results Program. n.d. Available: http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"2025100308224116000_13.1.e009349.42","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.97","article-title":"Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey","volume":"7","author":"Landgren","year":"2017","journal-title":"Blood Cancer J"},{"key":"2025100308224116000_13.1.e009349.43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"2025100308224116000_13.1.e009349.44","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100308224116000_13.1.e009349.45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/bloodadvances.2023010894","article-title":"Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy","volume":"8","author":"Peres","year":"2024","journal-title":"Blood Adv"},{"key":"2025100308224116000_13.1.e009349.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"2025100308224116000_13.1.e009349.47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100308224116000_13.1.e009349.48","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"2025100308224116000_13.1.e009349.49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"2025100308224116000_13.1.e009349.50","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0592"},{"key":"2025100308224116000_13.1.e009349.51","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jgo.2021.08.004","article-title":"Geriatric-assessment-identified functional deficits among adults with multiple myeloma with normal performance status","volume":"13","author":"Jensen","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"2025100308224116000_13.1.e009349.52","article-title":"Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy","volume":"30","author":"Johnson","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025100308224116000_13.1.e009349.53","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jtct.2023.12.015","article-title":"Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed\/Refractory Multiple Myeloma","volume":"30","author":"Davis","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025100308224116000_13.1.e009349.54","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300236","article-title":"Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials","volume":"3","author":"Kaur","year":"2024","journal-title":"NEJM Evid"},{"key":"2025100308224116000_13.1.e009349.55","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3324\/haematol.2022.280678","article-title":"Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed\/refractory acute lymphoblastic leukemia","volume":"108","author":"Wayne","year":"2023","journal-title":"Haematologica"},{"key":"2025100308224116000_13.1.e009349.56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"2025100308224116000_13.1.e009349.57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134322","article-title":"Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis","volume":"136","author":"Berdeja","year":"2020","journal-title":"Blood"},{"key":"2025100308224116000_13.1.e009349.58","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jtct.2023.03.012","article-title":"Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transplant Cell Ther"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009349","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:22:52Z","timestamp":1759504972000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,23]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-009349"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009349","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}